Skip to main content
NCBI home page
The Western Journal of Medicine logoLink to The Western Journal of Medicine
. 1998 Mar;168(3):176–181.

Nitric oxide and septic shock. From bench to bedside.

S J Kuhl 1, H Rosen 1
PMCID: PMC1304857  PMID: 9549416

Abstract

Refractory hypotension with end-organ hypoperfusion is an ominous feature of inflammatory shock. In the past fifteen years, nitric oxide (a diffusible, short-lived product of arginine metabolism) has been found to be an important regulatory molecule in several areas of metabolism, including vascular tone control. Vascular endothelial cells constitutively produce low levels of nitric oxide that regulate blood pressure by mediating adjacent smooth-muscle relaxation. In an inflammatory shock state, cytokines, like interleukin-1 and tumor necrosis factor-alpha, induce a separate, high-output form of the enzyme that synthesizes nitric oxide in both endothelial and smooth-muscle cells. The ensuing high rates of nitric oxide formation result in extensive smooth-muscle relaxation, pressor refractory vasodilation, and--ultimately--shock. The concept of the pathogenesis of inflammatory shock explains many limitations of current therapies and may foster the development of new interventions to mitigate the effects of nitric oxide overproduction in this syndrome.

Full text

PDF
176

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Auphan N., DiDonato J. A., Rosette C., Helmberg A., Karin M. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science. 1995 Oct 13;270(5234):286–290. doi: 10.1126/science.270.5234.286. [DOI] [PubMed] [Google Scholar]
  2. Bernard G. R., Wheeler A. P., Russell J. A., Schein R., Summer W. R., Steinberg K. P., Fulkerson W. J., Wright P. E., Christman B. W., Dupont W. D. The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. N Engl J Med. 1997 Mar 27;336(13):912–918. doi: 10.1056/NEJM199703273361303. [DOI] [PubMed] [Google Scholar]
  3. Bogdan C., Nathan C. Modulation of macrophage function by transforming growth factor beta, interleukin-4, and interleukin-10. Ann N Y Acad Sci. 1993 Jun 23;685:713–739. doi: 10.1111/j.1749-6632.1993.tb35934.x. [DOI] [PubMed] [Google Scholar]
  4. Bone R. C., Balk R. A., Fein A. M., Perl T. M., Wenzel R. P., Reines H. D., Quenzer R. W., Iberti T. J., Macintyre N., Schein R. M. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group. Crit Care Med. 1995 Jun;23(6):994–1006. doi: 10.1097/00003246-199506000-00003. [DOI] [PubMed] [Google Scholar]
  5. Bone R. C. Gram-positive organisms and sepsis. Arch Intern Med. 1994 Jan 10;154(1):26–34. [PubMed] [Google Scholar]
  6. Bone R. C. How gram-positive organisms cause sepsis. J Crit Care. 1993 Mar;8(1):51–59. doi: 10.1016/0883-9441(93)90033-h. [DOI] [PubMed] [Google Scholar]
  7. Bone R. C. Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: what we do and do not know about cytokine regulation. Crit Care Med. 1996 Jan;24(1):163–172. doi: 10.1097/00003246-199601000-00026. [DOI] [PubMed] [Google Scholar]
  8. De Kimpe S. J., Kengatharan M., Thiemermann C., Vane J. R. The cell wall components peptidoglycan and lipoteichoic acid from Staphylococcus aureus act in synergy to cause shock and multiple organ failure. Proc Natl Acad Sci U S A. 1995 Oct 24;92(22):10359–10363. doi: 10.1073/pnas.92.22.10359. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Dentener M. A., Von Asmuth E. J., Francot G. J., Marra M. N., Buurman W. A. Antagonistic effects of lipopolysaccharide binding protein and bactericidal/permeability-increasing protein on lipopolysaccharide-induced cytokine release by mononuclear phagocytes. Competition for binding to lipopolysaccharide. J Immunol. 1993 Oct 15;151(8):4258–4265. [PubMed] [Google Scholar]
  10. Fisher C. J., Jr, Agosti J. M., Opal S. M., Lowry S. F., Balk R. A., Sadoff J. C., Abraham E., Schein R. M., Benjamin E. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med. 1996 Jun 27;334(26):1697–1702. doi: 10.1056/NEJM199606273342603. [DOI] [PubMed] [Google Scholar]
  11. Fisher C. J., Jr, Dhainaut J. F., Opal S. M., Pribble J. P., Balk R. A., Slotman G. J., Iberti T. J., Rackow E. C., Shapiro M. J., Greenman R. L. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA. 1994 Jun 15;271(23):1836–1843. [PubMed] [Google Scholar]
  12. Furchgott R. F., Zawadzki J. V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980 Nov 27;288(5789):373–376. doi: 10.1038/288373a0. [DOI] [PubMed] [Google Scholar]
  13. Greenberg R. N., Wilson K. M., Kunz A. Y., Wedel N. I., Gorelick K. J. Observations using antiendotoxin antibody (E5) as adjuvant therapy in humans with suspected, serious, gram-negative sepsis. Crit Care Med. 1992 Jun;20(6):730–735. doi: 10.1097/00003246-199206000-00005. [DOI] [PubMed] [Google Scholar]
  14. Greenman R. L., Schein R. M., Martin M. A., Wenzel R. P., MacIntyre N. R., Emmanuel G., Chmel H., Kohler R. B., McCarthy M., Plouffe J. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group. JAMA. 1991 Aug 28;266(8):1097–1102. [PubMed] [Google Scholar]
  15. Gómez-Jiménez J., Salgado A., Mourelle M., Martín M. C., Segura R. M., Peracaula R., Moncada S. L-arginine: nitric oxide pathway in endotoxemia and human septic shock. Crit Care Med. 1995 Feb;23(2):253–258. doi: 10.1097/00003246-199502000-00009. [DOI] [PubMed] [Google Scholar]
  16. Heneka M. T., Löschmann P. A., Osswald H. Polymerized hemoglobin restores cardiovascular and kidney function in endotoxin-induced shock in the rat. J Clin Invest. 1997 Jan 1;99(1):47–54. doi: 10.1172/JCI119132. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Hibbs J. B., Jr, Westenfelder C., Taintor R., Vavrin Z., Kablitz C., Baranowski R. L., Ward J. H., Menlove R. L., McMurry M. P., Kushner J. P. Evidence for cytokine-inducible nitric oxide synthesis from L-arginine in patients receiving interleukin-2 therapy. J Clin Invest. 1992 Mar;89(3):867–877. doi: 10.1172/JCI115666. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Ignarro L. J., Fukuto J. M., Griscavage J. M., Rogers N. E., Byrns R. E. Oxidation of nitric oxide in aqueous solution to nitrite but not nitrate: comparison with enzymatically formed nitric oxide from L-arginine. Proc Natl Acad Sci U S A. 1993 Sep 1;90(17):8103–8107. doi: 10.1073/pnas.90.17.8103. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Ignarro L. J., Ross G., Tillisch J. Pharmacology of endothelium-derived nitric oxide and nitrovasodilators. West J Med. 1991 Jan;154(1):51–62. [PMC free article] [PubMed] [Google Scholar]
  20. Kilbourn R. G., Szabó C., Traber D. L. Beneficial versus detrimental effects of nitric oxide synthase inhibitors in circulatory shock: lessons learned from experimental and clinical studies. Shock. 1997 Apr;7(4):235–246. doi: 10.1097/00024382-199704000-00001. [DOI] [PubMed] [Google Scholar]
  21. Lefering R., Neugebauer E. A. Steroid controversy in sepsis and septic shock: a meta-analysis. Crit Care Med. 1995 Jul;23(7):1294–1303. doi: 10.1097/00003246-199507000-00021. [DOI] [PubMed] [Google Scholar]
  22. Leone A. M., Francis P. L., Rhodes P., Moncada S. A rapid and simple method for the measurement of nitrite and nitrate in plasma by high performance capillary electrophoresis. Biochem Biophys Res Commun. 1994 Apr 29;200(2):951–957. doi: 10.1006/bbrc.1994.1542. [DOI] [PubMed] [Google Scholar]
  23. Lorente J. A., Landín L., De Pablo R., Renes E., Liste D. L-arginine pathway in the sepsis syndrome. Crit Care Med. 1993 Sep;21(9):1287–1295. doi: 10.1097/00003246-199309000-00010. [DOI] [PubMed] [Google Scholar]
  24. MacMicking J. D., Nathan C., Hom G., Chartrain N., Fletcher D. S., Trumbauer M., Stevens K., Xie Q. W., Sokol K., Hutchinson N. Altered responses to bacterial infection and endotoxic shock in mice lacking inducible nitric oxide synthase. Cell. 1995 May 19;81(4):641–650. doi: 10.1016/0092-8674(95)90085-3. [DOI] [PubMed] [Google Scholar]
  25. McCloskey R. V., Straube R. C., Sanders C., Smith S. M., Smith C. R. Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group. Ann Intern Med. 1994 Jul 1;121(1):1–5. doi: 10.7326/0003-4819-121-1-199407010-00001. [DOI] [PubMed] [Google Scholar]
  26. Nava E., Palmer R. M., Moncada S. Inhibition of nitric oxide synthesis in septic shock: how much is beneficial? Lancet. 1991 Dec 21;338(8782-8783):1555–1557. doi: 10.1016/0140-6736(91)92375-c. [DOI] [PubMed] [Google Scholar]
  27. Palmer R. M., Ferrige A. G., Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 1987 Jun 11;327(6122):524–526. doi: 10.1038/327524a0. [DOI] [PubMed] [Google Scholar]
  28. Petros A., Bennett D., Vallance P. Effect of nitric oxide synthase inhibitors on hypotension in patients with septic shock. Lancet. 1991 Dec 21;338(8782-8783):1557–1558. doi: 10.1016/0140-6736(91)92376-d. [DOI] [PubMed] [Google Scholar]
  29. Petros A., Lamb G., Leone A., Moncada S., Bennett D., Vallance P. Effects of a nitric oxide synthase inhibitor in humans with septic shock. Cardiovasc Res. 1994 Jan;28(1):34–39. doi: 10.1093/cvr/28.1.34. [DOI] [PubMed] [Google Scholar]
  30. Pugin J., Heumann I. D., Tomasz A., Kravchenko V. V., Akamatsu Y., Nishijima M., Glauser M. P., Tobias P. S., Ulevitch R. J. CD14 is a pattern recognition receptor. Immunity. 1994 Sep;1(6):509–516. doi: 10.1016/1074-7613(94)90093-0. [DOI] [PubMed] [Google Scholar]
  31. Reinhart K., Wiegand-Löhnert C., Grimminger F., Kaul M., Withington S., Treacher D., Eckart J., Willatts S., Bouza C., Krausch D. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. Crit Care Med. 1996 May;24(5):733–742. doi: 10.1097/00003246-199605000-00003. [DOI] [PubMed] [Google Scholar]
  32. Scheinman R. I., Cogswell P. C., Lofquist A. K., Baldwin A. S., Jr Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science. 1995 Oct 13;270(5234):283–286. doi: 10.1126/science.270.5234.283. [DOI] [PubMed] [Google Scholar]
  33. Snyder S. H., Bredt D. S. Biological roles of nitric oxide. Sci Am. 1992 May;266(5):68-71, 74-7. doi: 10.1038/scientificamerican0592-68. [DOI] [PubMed] [Google Scholar]
  34. Thomas E. L., Aune T. M. Peroxidase-catalyzed oxidation of protein sulfhydryls mediated by iodine. Biochemistry. 1977 Aug 9;16(16):3581–3586. doi: 10.1021/bi00635a013. [DOI] [PubMed] [Google Scholar]
  35. Thomas G., Cole E. A., Ramwell P. W. NG-monomethyl L-arginine is a non-specific inhibitor of vascular relaxation. Eur J Pharmacol. 1989 Oct 24;170(1-2):123–124. doi: 10.1016/0014-2999(89)90148-9. [DOI] [PubMed] [Google Scholar]
  36. Wong J. M., Billiar T. R. Regulation and function of inducible nitric oxide synthase during sepsis and acute inflammation. Adv Pharmacol. 1995;34:155–170. doi: 10.1016/s1054-3589(08)61084-4. [DOI] [PubMed] [Google Scholar]
  37. Ziegler E. J., Fisher C. J., Jr, Sprung C. L., Straube R. C., Sadoff J. C., Foulke G. E., Wortel C. H., Fink M. P., Dellinger R. P., Teng N. N. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med. 1991 Feb 14;324(7):429–436. doi: 10.1056/NEJM199102143240701. [DOI] [PubMed] [Google Scholar]
  38. Ziegler E. J., McCutchan J. A., Fierer J., Glauser M. P., Sadoff J. C., Douglas H., Braude A. I. Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med. 1982 Nov 11;307(20):1225–1230. doi: 10.1056/NEJM198211113072001. [DOI] [PubMed] [Google Scholar]

Articles from Western Journal of Medicine are provided here courtesy of BMJ Publishing Group

RESOURCES